Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Globe Newswire•29/10/2026•16:05 ET
0
Key Highlights
- ➤Q1 revenue $1.415 billion, up 6% year over year
- ➤GAAP diluted EPS $2.92, up 23% year over year
- ➤More than $1.0 billion returned to shareholders through Q1 repurchases and dividends
- ➤FY2027 revenue guidance maintained at $5.75-$5.85 billion
- ➤FY2027 non-GAAP diluted EPS guidance maintained at $12.00-$12.25
Expert Statements
Mick Farrell, Chairman and CEO of Resmed
“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business.”
Mick Farrell, Chairman and CEO of Resmed
“Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%. Our strong free cash flow and the proceeds from our divestiture of MatrixCare enabled us to both invest in innovation and return more than $1 billion to shareholders during the quarter.”
Mick Farrell, Chairman and CEO of Resmed
“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”
* Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basis * Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91 * Returned more than $1.0 billion to shareholders through share repurchases and dividends during Q1 Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2026.
Get started
Create a free account to read the full story.